BiotechTube
Actipulse Neuroscience

Actipulse Neuroscience

San Francisco, United States· Est.
actipulseneuroscience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Actipulse Neuroscience is a clinical-stage neurotech company developing novel non-invasive brain stimulation devices for central nervous system disorders. Backed by Y Combinator and operating as a Paris Brain Institute company, it leverages a proprietary platform of high-frequency magnetic pulse technology. Its lead program for Major Depressive Disorder is in Phase 3, with a preclinical pipeline targeting oncology and other CNS conditions. The company aims to become the gold standard in neuromodulation within five years.

PsychiatryNeurologyOncology

Technology Platform

Non-invasive transcranial neuromodulation using high-frequency magnetic pulses, potentially leveraging nanotechnology for targeted stimulation of pathogenic mechanisms in CNS disorders.

Opportunities

The massive and growing unmet need in treatment-resistant depression and neurodegenerative diseases presents a multi-billion dollar market.
Success in Phase 3 could validate a novel platform with applications beyond psychiatry, including oncology and targeted drug delivery, creating multiple shots on goal.
Backing by Y Combinator and the Paris Brain Institute provides strong validation and access to expertise and networks.

Risk Factors

High clinical risk associated with the pivotal Phase 3 trial in depression, where failure would be catastrophic.
Facing established competition in the TMS market from companies with commercial infrastructure and approved devices.
As a pre-revenue private company, it is dependent on external financing to fund expensive clinical development and future commercialization efforts.

Competitive Landscape

Actipulse competes in the non-invasive brain stimulation market against established TMS device companies like Neuronetics (NeuroStar), BrainsWay, and MagVenture. It must demonstrate superior efficacy, tolerability, or convenience to gain market share. It also faces potential competition from pharmaceutical therapies, emerging neurotech companies (e.g., with tDCS, tACS), and advanced surgical neuromodulation approaches.

More companies in Neuroscience & CNS →More companies in United States →